Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Plug Power Inc (PLUG) vs Viatris Inc (VTRS) Price & Performance

Plug Power IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Plug Power Inc vs Viatris Inc — how do they compare? Plug Power Inc trades at $1.75 (market cap $2.49B), while Viatris Inc trades at $17.4 (market cap $20.12B). The key difference: Viatris Inc is far larger — about 8.1× Plug Power Inc's market cap, and Viatris Inc pays a 2.74% dividend while Plug Power Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Plug Power Inc for 41 Days and Viatris Inc for 57 Days on average.

PLUGVTRS
Market Cap
$2.49B$20.12B
Volume
47,846,3497,543,511
Sector
IndustrialsHealth
52-Week High
$4.14$18.27
52-Week Low
$1.73$9.74
Typical Hold Time
41 Days57 Days
Enterprise Value
$3.36B$32.24B
Dividend Yield
—2.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Plug Power Inc

Plug Power (PLUG) trades at $1.78, down 4.3% today, with a bearish technical outlook and negative earnings momentum. The company continues to report significant losses with a net income margin of -220.59% and negative cash flow, though recent news highlights strategic partnerships including a 280 MW electrolyzer agreement with Arcadia eFuels. Analyst consensus shows mixed sentiment with 44.7% buy ratings and a $3.13 price target, representing 76% upside potential from current levels.

While PLUG shows potential through hydrogen infrastructure expansion and recent contract wins, the investment case remains high-risk due to persistent negative profitability, cash burn, and competitive pressures. The stock trades near analyst low targets, suggesting limited downside protection, making it suitable only for speculative investors comfortable with substantial volatility and execution risk in the clean energy sector.

Viatris Inc

Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.

The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

PLUG
75% Buy25% Sell
Avg holding period · 41 Days
VTRS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Plug Power Inc

Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.

Read more on PLUG →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →